Gellért Perényi
Biographic Data
| ID | 8450350 |
|---|---|
| NAME | Gellért Perényi |
| GIVEN NAMES | Gellért |
| FAMILY NAME | Perényi |
| SIGNATURE | PERÉNYI G |
| AFFILIATIONS | University of Zurich |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Drug Prices After Patent Expirations in High-Income Countries and Implications for Cost-Effectiveness Analyses
The findings of this cohort study demonstrate that drug prices were reduced substantially after patent expirations in high-income countries. Therefore, incorporating information on patent status and pricing dynamics in cost-effectiveness assessment analyses is necessary for producing accurate economic evaluations of new drugs
Investments in Research and Development for Supplemental Drug Indications—Implications for Drug Price Negotiations
This Viewpoint compares the research and development costs for a drug’s first indication with supplemental indications to demonstrate that the cost of approval for supplemental indications may be substantially lower
No prominent works on this page.
Investments in Research and Development for Supplemental Drug Indications—Implications for Drug Price Negotiations
This Viewpoint compares the research and development costs for a drug’s first indication with supplemental indications to demonstrate that the cost of approval for supplemental indications may be substantially lower
Drug Prices After Patent Expirations in High-Income Countries and Implications for Cost-Effectiveness Analyses
The findings of this cohort study demonstrate that drug prices were reduced substantially after patent expirations in high-income countries. Therefore, incorporating information on patent status and pricing dynamics in cost-effectiveness assessment analyses is necessary for producing accurate economic evaluations of new drugs
Business (2 works) · Drug prices (2 works) · Economics (2 works) · Health Systems, Economic Evaluations, Quality of Life (2 works) · Medicine (2 works) · Pharmaceutical Economics and Policy (2 works) · Public economics (2 works) · Actuarial science (1 work) · Affect (linguistics (1 work) · Biosimilars and Bioanalytical Methods (1 work)